← Reports

Listed Korea Healthcare R&D Scoreboard — Q3 2026

Full census of 403 KOSPI/KOSDAQ-listed medical AI, biotech and device companies · five public sources joined at the company level · computed 2026-09-30 · published quarterly

This scoreboard joins official records from Korea's MFDS, the US FDA, PubMed, KIPRIS and ClinicalTrials.gov at the company level to measure, each quarter, how research in Korea's listed healthcare sector converts into products and market entries. Every figure is a tally of primary regulatory records; methods and limitations are disclosed below. Citation is free with attribution to the MAA R&D Scoreboard.

Published 2026-09-04 · Corrected 2026-10-07 · Measured 2026-09-30 · Medical AI Alliance

Key findings

1
First-ever US FDA entrants (12 mo)
▼ 3 a year earlier
26.0%
Korean approval → US record
74 of 285 companies
312
Active global trials (n)
57 in Phase 3 · 84 companies
761
Publications (12 mo)
▲ +11.1% YoY
43%
510(k) share of radiology (24 mo)
46 of 107

— 1 listed company made its first-ever US FDA filing in the past twelve months, down from 3 a year earlier.

— Of 285 listed companies holding Korean approvals, 74 (26.0%) also hold a US FDA record.

— The forward pipeline is expanding: 312 active clinical trials worldwide across 84 companies, including 57 Phase 3 trials.

— Research output rose: 761 PubMed-indexed publications in the past twelve months, +11.1% year on year.

— Radiology accounts for 43% of Korean 510(k) clearances over 24 months — imaging is Korea's gateway to the US market.

1. US market entry — fewer newcomers, incumbents carry the activity

ASTERASYS was the only listed Korean healthcare company to make a first-ever US FDA filing in the past twelve months. The preceding twelve months produced 3 first-time entrants (HLB · HLB Life Science · MEKICS).

Activity among companies already in the US market continued. The most active filers over the past twelve months:

CompanyFDA filings, last 12 months (n)
1L&K BIOMED
6
2NEUROPHET
3
3Vieworks
3
4CLASSYS
2
5DRTECH
2
6SEJONG MEDICAL
2
7Lunit
2
8RecensMedical
2
9Ray
2
10Celltrion
2

"First-ever" is verified per candidate against openFDA applicant records; two candidates with earlier filings (2012, 2009) were excluded by this check.

2. Where Korea enters — radiology is the gateway

46 of 107 Korean 510(k) clearances over the past 24 months (43%) fall under the Radiology review panel.

Radiology
46
General, Plastic Surgery
25
Orthopedic
18
Dental
8
Neurology
3
Gastroenterology, Urology
3
Anesthesiology
2
General Hospital
2
clearances · past 24 months

Korean AI reading software is classified under radiology, which this distribution reflects.

3. The global trial pipeline — 312 active trials, 57 in Phase 3

Korean listed companies sponsor 312 active trials worldwide. By phase: 103 in Phase 1, 68 in Phase 2, 57 in Phase 3 and 16 in Phase 4 (68 unphased — observational and other).

Companies with the largest active portfolios:

Phase 1
103
Phase 2
68
Phase 3
57
Phase 4
16
Phase not stated
68
trials · active
CompanyActive global trials (n)
1YUHAN
33
2DAEWOONG PHARMA
27
3Boryung
23
4Hanmi Pharm
13
5Chong Kun Dang Pharmaceutical
12
6HK inno.N
11
7GC Biopharma
10
8DONG-A ST
10
9Onconic Therapeutics
8
10Celltrion
7

ClinicalTrials.gov registrations, matched by exact lead-sponsor name. CRO-sponsored registrations are not captured.

4. Domestic regulatory flow — nine full quarters

Domestic pipeline inflow remains steady across approvals and trial authorisations:

824Q27124Q37224Q46325Q17325Q27925Q37725Q46926Q17726Q27426Q3*
MFDS trial authorisations (* quarter in progress)
QuarterMFDS devicesMFDS drugsTrial authorisationsFDA 510(k)FDA drugs
2024Q21117832
2024Q316914471141
2024Q416017172191
2025Q110815763234
2025Q211318073110
2025Q31962447990
2025Q418618477141
2026Q11791776991
2026Q218726077200
2026Q3 (partial)1971937471

The current quarter is partial. Read the trend, not a single bar.

5. Trial authorisation leaders

The most active recipients of Korean trial authorisations over the past twelve months — all five leaders are established pharmaceutical companies. These authorisations include bioequivalence studies for generics, so they should not be read as the size of the new-drug pipeline; our R&D Investment and Output report counts bioequivalence separately.

CompanyTrial authorisations, 12 months (n)
1DAEWOONG PHARMA
20
2HUONS
15
3Boryung
13
4WHANIN PHARM
13
5Chong Kun Dang Pharmaceutical
11
6KyungdongPharm
10
7Hanmi Pharm
10
8DongKoo Bio & Pharma
10
9HLB PHARMACEUTICAL
9
10YUHAN
9

6. Commercialisation signals — supply and licensing disclosures

As a leading indicator of commercialisation, we tally Korea Exchange disclosures of supply contracts and technology transfer/licensing agreements: 377 over the last four full quarters.

2024Q3*6924Q44825Q114425Q29625Q312025Q46726Q19426Q27926Q3*
contract disclosures (* partial quarter)

The collection window opens in Q3 2024; the first quarter is partial.

7. The research base — publications up year on year

761 PubMed-indexed publications in the past twelve months, +11.1% versus the prior period. The most prolific publishers:

CompanyPublications, 12 months (n)
1SEEGENE
39
2Hanmi Pharm
37
3Lunit
31
43billion
30
5ILDONG HOLDINGS
19
6JLK
18
7YUHAN
18
8VUNO
18
9Celltrion
17
10NEUROPHET
14

Matched by author affiliation. The index also holds domestic and foreign patents; a company ranking is withheld until non-healthcare patents of diversified groups can be separated.

8. From research to product — conversion by sector

Among companies holding research assets (publications or patents), the share that has reached a product approval. The gap between medical devices (93.7%) and biotech (44.6%) quantifies the two sectors' different development cycles and regulatory structures.

Medical devices
93.7%
Medical AI
81.2%
Pharma & CDMO
78.2%
Biotech & drug discovery
44.6%
Healthcare infrastructure
33.3%
Share of research-holding companies reaching approval
SectorCompaniesWith research assetsIn clinical stageWith approvalsResearch-to-product rate
Medical devices1261262011893.7%
Pharma & CDMO126124979778.2%
Biotech & drug discovery113112815044.6%
Healthcare infrastructure22215733.3%
Medical AI161661381.2%

Biotech's lower rate is development in progress, not failure — 81 of the sector's 113 companies are in the clinical stage. Device "approvals" include Class I notifications, which need no review, so the device rate runs high (our R&D Investment and Output report excludes them).

9. New entrants

First-ever Korean trial authorisation in the past twelve months: Aprogen · BIONEER · INGENIA Therapeutics · Keeps Biopharma · ORGANOIDSCIENCES. First-ever product approval: Curocell · IMGT.

Trial data begins in 2012. Records predating corporate mergers may not carry over to the present entity.

Method and limits

Population — the complete census of 403 KOSPI/KOSDAQ-listed medical AI, biotech and medical device companies (the MAA index). A census, not a sample. 19 index constituents whose main business is not healthcare (oil refining, food, security software and the like) are excluded from these tallies.

Sources — Korea MFDS (data.go.kr), US FDA openFDA, PubMed, KIPRIS and ClinicalTrials.gov. Records are matched by business registration number or exact corporate-name match after stripping legal suffixes; similarity matching is never used.

Subsidiaries — records filed by subsidiaries are counted under the listed parent only where control is confirmed in DART filings, and are labelled as subsidiary filings. Coverage is a floor.

Direction of error — filings under US-subsidiary names and CRO-sponsored trials are not captured. Every known error is conservative; there is no overcounting path.

Verification — figures naming companies were re-queried against the source agency through an independent path; exclusions are disclosed in the text. Errors reported to us are recomputed and corrected with a visible history. Underlying records for any company are available on request.

Edition history — first published 2026-09-04 (provisional until the 30 September basis date) → 2026-09-24 provisional update: 19 companies whose main business is not healthcare were removed, and one sector assignment (Daewoong Pharmaceutical) and the publication matching were corrected (sector conversion rates changed) → 2026-10-06 fixed at the 30 September basis (frozen thereafter), adding patents for companies whose applicant numbers were newly matched → 2026-10-07 correction: global trials of 12 companies missed through sponsor-name variants were linked (active trials 268 → 312, companies 76 → 84) and three sector assignments corrected. The same day, four sentences whose figures disagreed with the tables (section 3 heading, section 8 rate and note, section 9 count) and the reading in section 5 (trial authorisations include bioequivalence studies, so they are not the size of the new-drug pipeline) were corrected. Updates before 6 October were not marked at the time.

This report is based entirely on public information and may be quoted freely. Please cite Medical AI Alliance as the source.